Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2026

1.

Treatment of cancer stem cells from human colon adenocarcinoma cell line HT-29 with resveratrol and sulindac induced mesenchymal-endothelial transition rate.

Pouyafar A, Rezabakhsh A, Rahbarghazi R, Heydarabad MZ, Shokrollahi E, Sokullu E, Khaksar M, Nourazarian A, Avci ÇB.

Cell Tissue Res. 2019 Feb 13. doi: 10.1007/s00441-019-02998-9. [Epub ahead of print]

PMID:
30758710
2.

Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs.

Dell'Omo G, Crescenti D, Vantaggiato C, Parravicini C, Borroni AP, Rizzi N, Garofalo M, Pinto A, Recordati C, Scanziani E, Bassi FD, Pruneri G, Conti P, Eberini I, Maggi A, Ciana P.

Br J Cancer. 2019 Feb 11. doi: 10.1038/s41416-018-0372-7. [Epub ahead of print]

PMID:
30739913
3.

Efficacy and Safety of Oral Premedication on Pain after Nonsurgical Root Canal Treatment: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.

Nagendrababu V, Pulikkotil SJ, Jinatongthai P, Veettil SK, Teerawattanapong N, Gutmann JL.

J Endod. 2019 Feb 5. pii: S0099-2399(18)30750-7. doi: 10.1016/j.joen.2018.10.016. [Epub ahead of print] Review.

PMID:
30737050
4.

Erratum: Chemopreventive effect of sulindac in combination with epigallocatechin gallate or kaempferol against 1,2-dimethyl hydrazine-induced preneoplastic lesions in rats: A Comparative Study.

[No authors listed]

J Biochem Mol Toxicol. 2019 Feb;33(2):e22284. doi: 10.1002/jbt.22284. Epub 2019 Jan 16. No abstract available.

PMID:
30730596
5.

Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.

Zhang M, Srichai MB, Zhao M, Chen J, Davis LS, Wu G, Breyer MD, Hao CM.

Int J Med Sci. 2019 Jan 1;16(1):180-188. doi: 10.7150/ijms.27719. eCollection 2019.

6.

Sulindac imprinted mungbean starch/PVA biomaterial films as a transdermal drug delivery patch.

Tak HY, Yun YH, Lee CM, Yoon SD.

Carbohydr Polym. 2019 Mar 15;208:261-268. doi: 10.1016/j.carbpol.2018.12.076. Epub 2018 Dec 24.

PMID:
30658799
7.

Inhibition of Polyamine Biosynthesis Reverses Ca2+ Channel Remodeling in Colon Cancer Cells.

Gutiérrez LG, Hernández-Morales M, Núñez L, Villalobos C.

Cancers (Basel). 2019 Jan 13;11(1). pii: E83. doi: 10.3390/cancers11010083.

8.

Design, synthesis and biological evaluation of tetrazole-containing RXRα ligands as anticancer agents.

Yan Z, Chong S, Lin H, Yang Q, Wang X, Zhang W, Zhang X, Zeng Z, Su Y.

Eur J Med Chem. 2019 Feb 15;164:562-575. doi: 10.1016/j.ejmech.2018.12.036. Epub 2018 Dec 19.

PMID:
30634084
9.

The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery.

Wen Z, Muratomi N, Huang W, Huang L, Ren J, Yang J, Persaud Y, Loloi J, Mallangada N, Kung P, Honkanen R, Rigas B.

Int J Pharm. 2019 Feb 25;557:273-279. doi: 10.1016/j.ijpharm.2018.12.057. Epub 2018 Dec 28.

10.

Pharmacological targeting of RAS: Recent success with direct inhibitors.

O'Bryan JP.

Pharmacol Res. 2019 Jan;139:503-511. doi: 10.1016/j.phrs.2018.10.021. Epub 2018 Oct 23. Review.

11.

Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 2.

Aono Y, Horinaka M, Iizumi Y, Watanabe M, Taniguchi T, Yasuda S, Sakai T.

Biochem Biophys Res Commun. 2018 Nov 10;505(4):1203-1210. doi: 10.1016/j.bbrc.2018.10.050. Epub 2018 Oct 14.

PMID:
30327144
12.

In silico evidence of direct interaction between statins and β-amyloid.

Shakour N, Bianconi V, Pirro M, Barreto GE, Hadizadeh F, Sahebkar A.

J Cell Biochem. 2019 Mar;120(3):4710-4715. doi: 10.1002/jcb.27761. Epub 2018 Sep 27.

PMID:
30260016
13.

An Ex Vivo Fermentation Screening Platform to Study Drug Metabolism by Human Gut Microbiota.

van de Steeg E, Schuren FHJ, Obach RS, van Woudenbergh C, Walker GS, Heerikhuisen M, Nooijen IHG, Vaes WHJ.

Drug Metab Dispos. 2018 Nov;46(11):1596-1607. doi: 10.1124/dmd.118.081026. Epub 2018 Aug 29.

PMID:
30158249
14.

Pharmacological and dietary factors in prevention of colorectal cancer.

Waluga M, Zorniak M, Fichna J, Kukla M, Hartleb M.

J Physiol Pharmacol. 2018 Jun;69(3). doi: 10.26402/jpp.2018.3.02. Epub 2018 Aug 22. Review.

15.

Rationally Developed Metallogelators Derived from Pyridyl Derivatives of NSAIDs Displaying Anti-Inflammatory and Anticancer Activities.

Sarkar K, Khasimbi S, Mandal S, Dastidar P.

ACS Appl Mater Interfaces. 2018 Sep 12;10(36):30649-30661. doi: 10.1021/acsami.8b09872. Epub 2018 Aug 30.

PMID:
30118200
16.

Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.

Mohammed A, Yarla NS, Madka V, Rao CV.

Int J Mol Sci. 2018 Aug 8;19(8). pii: E2332. doi: 10.3390/ijms19082332. Review.

17.

Overview of the structure-based non-genomic effects of the nuclear receptor RXRα.

Chen L, Wu L, Zhu L, Zhao Y.

Cell Mol Biol Lett. 2018 Aug 7;23:36. doi: 10.1186/s11658-018-0103-3. eCollection 2018. Review.

18.

Sulindac encapsulation and release from functional poly(HEMA) microparticles prepared in supercritical carbon dioxide.

Parilti R, Riva R, Howdle SM, Dupont-Gillain C, Jerome C.

Int J Pharm. 2018 Oct 5;549(1-2):161-168. doi: 10.1016/j.ijpharm.2018.07.060. Epub 2018 Jul 26.

PMID:
30056217
19.

Sulindac.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

20.

Chemopreventive effect of sulindac in combination with epigallocatechin gallate or kaempferol against 1,2-dimethyl hydrazine-induced preneoplastic lesions in rats: A Comparative Study.

Hassanein NMA, Hassan ESG, Hegab AM, Elahl HMS.

J Biochem Mol Toxicol. 2018 Oct;32(10):e22198. doi: 10.1002/jbt.22198. Epub 2018 Jul 12. Erratum in: J Biochem Mol Toxicol. 2019 Feb;33(2):e22284.

PMID:
29999212

Supplemental Content

Loading ...
Support Center